Abstract
Pharmacological manipulation of tau protein in Alzheimer's disease included microtubule-stabilizing agents, tau protein kinase inhibitors, tau aggregation inhibitors, active and passive immunotherapies and, more recently, inhibitors of tau acetylation. Animal studies have shown that both active and passive approaches can remove tau pathology and, in some cases, improve cognitive function. Two active vaccines targeting either nonphosphorylated (AAD-vac1) and phosphorylated tau (ACI-35) have entered Phase I testing. Notwithstanding, the recent discontinuation of the monoclonal antibody RG7345 for Alzheimer's disease, two other antitau antibodies, BMS-986168 and C2N-8E12, are also currently in Phase I testing for progressive supranuclear palsy. After the recent impressive results in animal studies obtained by salsalate, the dimer of salicylic acid, inhibitors of tau acetylation are being actively pursued.
| Original language | English |
|---|---|
| Pages (from-to) | 1119-1134 |
| Number of pages | 16 |
| Journal | Immunotherapy |
| Volume | 8 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - Sep 1 2016 |
Fingerprint
Keywords
- active immunotherapy
- Alzheimer's disease
- passive immunotherapy
ASJC Scopus subject areas
- Immunology and Allergy
- Oncology
- Immunology
Cite this
Tau-based therapeutics for Alzheimer's disease : Active and passive immunotherapy. / Panza, Francesco; Solfrizzi, Vincenzo; Seripa, Davide; Imbimbo, Bruno P.; Lozupone, Madia; Santamato, Andrea; Tortelli, Rosanna; Galizia, Ilaria; Prete, Camilla; Daniele, Antonio; Pilotto, Alberto; Greco, Antonio; Logroscino, Giancarlo.
In: Immunotherapy, Vol. 8, No. 9, 01.09.2016, p. 1119-1134.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Tau-based therapeutics for Alzheimer's disease
T2 - Active and passive immunotherapy
AU - Panza, Francesco
AU - Solfrizzi, Vincenzo
AU - Seripa, Davide
AU - Imbimbo, Bruno P.
AU - Lozupone, Madia
AU - Santamato, Andrea
AU - Tortelli, Rosanna
AU - Galizia, Ilaria
AU - Prete, Camilla
AU - Daniele, Antonio
AU - Pilotto, Alberto
AU - Greco, Antonio
AU - Logroscino, Giancarlo
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Pharmacological manipulation of tau protein in Alzheimer's disease included microtubule-stabilizing agents, tau protein kinase inhibitors, tau aggregation inhibitors, active and passive immunotherapies and, more recently, inhibitors of tau acetylation. Animal studies have shown that both active and passive approaches can remove tau pathology and, in some cases, improve cognitive function. Two active vaccines targeting either nonphosphorylated (AAD-vac1) and phosphorylated tau (ACI-35) have entered Phase I testing. Notwithstanding, the recent discontinuation of the monoclonal antibody RG7345 for Alzheimer's disease, two other antitau antibodies, BMS-986168 and C2N-8E12, are also currently in Phase I testing for progressive supranuclear palsy. After the recent impressive results in animal studies obtained by salsalate, the dimer of salicylic acid, inhibitors of tau acetylation are being actively pursued.
AB - Pharmacological manipulation of tau protein in Alzheimer's disease included microtubule-stabilizing agents, tau protein kinase inhibitors, tau aggregation inhibitors, active and passive immunotherapies and, more recently, inhibitors of tau acetylation. Animal studies have shown that both active and passive approaches can remove tau pathology and, in some cases, improve cognitive function. Two active vaccines targeting either nonphosphorylated (AAD-vac1) and phosphorylated tau (ACI-35) have entered Phase I testing. Notwithstanding, the recent discontinuation of the monoclonal antibody RG7345 for Alzheimer's disease, two other antitau antibodies, BMS-986168 and C2N-8E12, are also currently in Phase I testing for progressive supranuclear palsy. After the recent impressive results in animal studies obtained by salsalate, the dimer of salicylic acid, inhibitors of tau acetylation are being actively pursued.
KW - active immunotherapy
KW - Alzheimer's disease
KW - passive immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=84981263625&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84981263625&partnerID=8YFLogxK
U2 - 10.2217/imt-2016-0019
DO - 10.2217/imt-2016-0019
M3 - Review article
AN - SCOPUS:84981263625
VL - 8
SP - 1119
EP - 1134
JO - Immunotherapy
JF - Immunotherapy
SN - 1750-743X
IS - 9
ER -